Express News | Astria Therapeutics Announces Initiation of Phase 1a Trial of Star-0310, a Potential Best-in-Class Monoclonal Antibody Ox40 Antagonist for the Treatment of Atopic Dermatitis

ReutersJan 23 08:00 ET

Astria Therapeutics Announces Initiation of Phase 1a Trial of STAR-0310, a Potential Best-in-Class Monoclonal Antibody OX40 Antagonist for the Treatment of Atopic Dermatitis

BusinesswireJan 23 08:00 ET

Evercore Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $25

Moomoo NewsJan 16 08:31 ET · Ratings

LifeSci Capital Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Cuts Target Price to $22

Moomoo NewsJan 14 08:31 ET · Ratings

Oppenheimer Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $32

Moomoo NewsJan 14 08:31 ET · Ratings

Express News | Astria Therapeutics Inc : Jefferies Raises Target Price to $29 From $27

ReutersJan 13 10:39 ET

Astria Therapeutics Announces ALPHA-ORBIT Phase 3 Trial Design For Navenibart In HAE; Features 3- And 6-Month Dosing, Primary Analysis At 6 Months; Expected Q1 2025 Initiation And Early 2027 Results; Strong Financial Position Supports Until Top-Line...

BenzingaJan 13 08:20 ET

Express News | Astria Therapeutics Inc: Alpha-Orbit Top-Line Results Anticipated in Early 2027.

ReutersJan 13 08:03 ET

Astria Therapeutics Announces Design of ALPHA-ORBIT Pivotal Phase 3 Trial of Navenibart in HAE

Business WireJan 13 08:00 ET

Arm Holdings And Other Big Stocks Moving Lower In Monday's Pre-Market Session

BenzingaDec 23, 2024 08:35 ET

Why Rumble Shares Are Trading Higher By Around 43%; Here Are 20 Stocks Moving Premarket

BenzingaDec 23, 2024 07:42 ET

Top Premarket Decliners

MT NewswiresDec 16, 2024 07:51 ET

LifeSci Capital Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Maintains Target Price $23

Moomoo NewsDec 11, 2024 15:31 ET · Ratings

Oppenheimer Maintains Astria Therapeutics Inc(ATXS.US) With Buy Rating, Raises Target Price to $32

Moomoo NewsDec 11, 2024 12:31 ET · Ratings

Express News | Astria Therapeutics: Advancing Navenibart to Phase 3 Development With Trial Initiation Expected in Q1 2025

ReutersDec 11, 2024 08:02 ET

Express News | Astria Therapeutics Inc - Navenibart Shows Favorable Safety and Well-Tolerated Profile

ReutersDec 11, 2024 08:01 ET

Astria Therapeutics Announces Positive Final Results From Target Enrollment in the ALPHA-STAR Phase 1b/2 Trial of Navenibart for HAE

Business WireDec 11, 2024 08:00 ET

Express News | Astria Therapeutics Announces Positive Final Results From Target Enrollment in the Alpha-Star Phase 1B/2 Trial of Navenibart for Hae

ReutersDec 11, 2024 08:00 ET

Astria Therapeutics Announces FDA Clearance Of IND Application For STAR-0310, A Monoclonal Antibody OX40 Antagonist For The Treatment Of Atopic Dermatitis

BenzingaDec 10, 2024 08:06 ET

Express News | Astria Therapeutics Inc: Phase 1a Trial of Star-0310 in Healthy Volunteers Expected to Initiate in Q1 2025

ReutersDec 10, 2024 08:00 ET